Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DocGo Inc. stock logo
DCGO
DocGo
$3.61
+2.8%
$3.71
$2.78
$10.82
$376.05M0.96981,573 shs1.16 million shs
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
$3.95
+1.5%
$3.58
$2.82
$18.50
$20.62M-0.2227,726 shs16,026 shs
FONAR Co. stock logo
FONR
FONAR
$16.31
+0.3%
$19.89
$12.13
$24.05
$103.24M1.219,455 shs11,316 shs
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
$0.00
$0.07
$4.08
$3.50M2.57848,888 shsN/A
Surgalign Holdings, Inc. stock logo
SRGA
Surgalign
$0.76
$0.17
$6.77
$1.69M1.551.44 million shs8.72 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DocGo Inc. stock logo
DCGO
DocGo
0.00%0.00%-5.25%+4.94%-58.02%
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
-1.00%-5.50%+8.22%-9.82%-69.14%
FONAR Co. stock logo
FONR
FONAR
0.00%+0.25%-17.73%-17.83%+3.69%
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
0.00%0.00%0.00%0.00%+42.86%
Surgalign Holdings, Inc. stock logo
SRGA
Surgalign
0.00%0.00%0.00%0.00%-83.81%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
DocGo Inc. stock logo
DCGO
DocGo
4.6592 of 5 stars
4.53.00.00.01.63.33.8
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
1.4995 of 5 stars
3.53.00.00.00.01.70.6
FONAR Co. stock logo
FONR
FONAR
N/AN/AN/AN/AN/AN/AN/AN/A
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Surgalign Holdings, Inc. stock logo
SRGA
Surgalign
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DocGo Inc. stock logo
DCGO
DocGo
3.00
Buy$10.58193.17% Upside
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
3.00
Buy$11.00178.48% Upside
FONAR Co. stock logo
FONR
FONAR
N/AN/AN/AN/A
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
N/AN/AN/AN/A
Surgalign Holdings, Inc. stock logo
SRGA
Surgalign
N/AN/AN/AN/A

Current Analyst Ratings

Latest DCGO, FONR, EVAX, SRGA, and PHAS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/30/2024
DocGo Inc. stock logo
DCGO
DocGo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $6.50
4/11/2024
DocGo Inc. stock logo
DCGO
DocGo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$10.00 ➝ $9.00
4/10/2024
DocGo Inc. stock logo
DCGO
DocGo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$11.00 ➝ $8.00
4/10/2024
DocGo Inc. stock logo
DCGO
DocGo
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $11.00
4/3/2024
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00
4/2/2024
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$8.00
3/20/2024
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00
2/29/2024
DocGo Inc. stock logo
DCGO
DocGo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$13.00 ➝ $11.00
2/29/2024
DocGo Inc. stock logo
DCGO
DocGo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$11.00 ➝ $10.00
2/29/2024
DocGo Inc. stock logo
DCGO
DocGo
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $10.00
2/23/2024
DocGo Inc. stock logo
DCGO
DocGo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $11.00
(Data available from 5/5/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DocGo Inc. stock logo
DCGO
DocGo
$624.29M0.60$0.22 per share16.49$2.93 per share1.23
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
$70K294.56N/AN/A($1.17) per share-3.38
FONAR Co. stock logo
FONR
FONAR
$98.64M1.05$2.79 per share5.85$23.07 per share0.71
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
$818K0.00N/AN/A($1.93) per share0.00
Surgalign Holdings, Inc. stock logo
SRGA
Surgalign
$81.98M0.00N/AN/A($3.81) per share0.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DocGo Inc. stock logo
DCGO
DocGo
$6.86M$0.0751.5710.310.401.10%2.01%1.37%5/8/2024 (Confirmed)
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
-$22.12M-$6.76N/A30.38N/AN/A-451.63%-149.27%5/29/2024 (Estimated)
FONAR Co. stock logo
FONR
FONAR
$9.38M$1.848.86N/A12.63%8.47%6.45%5/20/2024 (Estimated)
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/A
Surgalign Holdings, Inc. stock logo
SRGA
Surgalign
-$54.60M-$8.12N/AN/AN/A-64.63%-983.11%-74.49%N/A

Latest DCGO, FONR, EVAX, SRGA, and PHAS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024N/A
DocGo Inc. stock logo
DCGO
DocGo
$0.09N/A-$0.09N/AN/AN/A  
3/27/2024Q4 2023
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
N/A-$0.16-$0.16-$0.16N/A$0.07 million
2/28/2024Q4 2023
DocGo Inc. stock logo
DCGO
DocGo
$0.13$0.06-$0.07$0.05$195.48 million$199.25 million
2/14/2024Q2 2024
FONAR Co. stock logo
FONR
FONAR
N/A$0.54+$0.54$0.54N/A$25.39 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
DocGo Inc. stock logo
DCGO
DocGo
N/AN/AN/AN/AN/A
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
N/AN/AN/AN/AN/A
FONAR Co. stock logo
FONR
FONAR
N/AN/AN/AN/AN/A
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
N/AN/AN/AN/AN/A
Surgalign Holdings, Inc. stock logo
SRGA
Surgalign
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DocGo Inc. stock logo
DCGO
DocGo
N/A
1.99
1.99
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
N/A
1.18
1.18
FONAR Co. stock logo
FONR
FONAR
N/A
9.35
9.15
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
N/A
0.47
0.47
Surgalign Holdings, Inc. stock logo
SRGA
Surgalign
N/A
2.67
2.00

Ownership

Institutional Ownership

CompanyInstitutional Ownership
DocGo Inc. stock logo
DCGO
DocGo
56.44%
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
11.04%
FONAR Co. stock logo
FONR
FONAR
50.64%
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
49.02%
Surgalign Holdings, Inc. stock logo
SRGA
Surgalign
26.31%

Insider Ownership

CompanyInsider Ownership
DocGo Inc. stock logo
DCGO
DocGo
13.78%
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
41.64%
FONAR Co. stock logo
FONR
FONAR
2.17%
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
9.90%
Surgalign Holdings, Inc. stock logo
SRGA
Surgalign
3.00%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
DocGo Inc. stock logo
DCGO
DocGo
4,164104.17 million89.82 millionOptionable
Evaxion Biotech A/S stock logo
EVAX
Evaxion Biotech A/S
495.22 million3.04 millionOptionable
FONAR Co. stock logo
FONR
FONAR
5616.33 million6.19 millionNot Optionable
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
6049.86 million44.92 millionNot Optionable
Surgalign Holdings, Inc. stock logo
SRGA
Surgalign
2179.24 million8.96 millionOptionable

DCGO, FONR, EVAX, SRGA, and PHAS Headlines

SourceHeadline
Surgalign Holdings Inc.Surgalign Holdings Inc.
thestreet.com - November 4 at 12:18 AM
Surgalign Holdings Inc (SRGAQ)Surgalign Holdings Inc (SRGAQ)
investing.com - August 15 at 6:57 AM
RT20.BE - SURGALIGN HLDGS NEW -,001RT20.BE - SURGALIGN HLDGS NEW -,001
finance.yahoo.com - July 10 at 8:46 AM
Why Is Surgalign Holdings (SRGA) Stock Up 10% Today?Why Is Surgalign Holdings (SRGA) Stock Up 10% Today?
investorplace.com - June 27 at 9:07 AM
Short Volatility Alert: Surgalign HoldingsShort Volatility Alert: Surgalign Holdings
benzinga.com - June 26 at 2:42 PM
Why Is Surgalign Holdings (SRGA) Stock Down 23% Today?Why Is Surgalign Holdings (SRGA) Stock Down 23% Today?
investorplace.com - June 26 at 10:03 AM
Surgalign Holdings, Inc.: Surgalign Receives NASDAQ Delisting Notice Following its Chapter 11 FilingSurgalign Holdings, Inc.: Surgalign Receives NASDAQ Delisting Notice Following its Chapter 11 Filing
finanznachrichten.de - June 23 at 3:32 PM
Surgalign receives Nasdaq delisting notice following bankruptcy filingSurgalign receives Nasdaq delisting notice following bankruptcy filing
massdevice.com - June 23 at 3:32 PM
Surgalign Receives NASDAQ Delisting Notice Following its Chapter 11 FilingSurgalign Receives NASDAQ Delisting Notice Following its Chapter 11 Filing
finance.yahoo.com - June 23 at 10:23 AM
Surgalign files Chapter 11 to sell global hardware, biologics businessSurgalign files Chapter 11 to sell global hardware, biologics business
massdevice.com - June 20 at 6:08 PM
Surgalign Files For Bankruptcy, Agrees To Sell Global Hardware & Biologics BusinessSurgalign Files For Bankruptcy, Agrees To Sell Global Hardware & Biologics Business
benzinga.com - June 20 at 1:07 PM
Surgalign Enters Into Definitive Agreement to Sell Global Hardware and Biologics Business Through a Structured Sale Process Under Chapter 11 of the U.S. Bankruptcy CodeSurgalign Enters Into Definitive Agreement to Sell Global Hardware and Biologics Business Through a Structured Sale Process Under Chapter 11 of the U.S. Bankruptcy Code
finance.yahoo.com - June 20 at 1:07 PM
Why Is Surgalign (SRGA) Stock Down 55% Today?Why Is Surgalign (SRGA) Stock Down 55% Today?
investorplace.com - June 20 at 10:06 AM
Surgalign plummets 42% on bankruptcy filingSurgalign plummets 42% on bankruptcy filing
msn.com - June 20 at 8:07 AM
Surgalign Plummets on Chapter 11 FilingSurgalign Plummets on Chapter 11 Filing
msn.com - June 20 at 8:07 AM
Medtech firm Surgalign files for Chapter 11 bankruptcyMedtech firm Surgalign files for Chapter 11 bankruptcy
dunyanews.tv - June 20 at 12:35 AM
Surgalign (SRGA) Upgraded to Buy: What Does It Mean for the Stock?Surgalign (SRGA) Upgraded to Buy: What Does It Mean for the Stock?
finance.yahoo.com - June 5 at 6:03 PM
Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Athira Pharma (ATHA) and Surgalign Holdings (SRGA)Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Athira Pharma (ATHA) and Surgalign Holdings (SRGA)
markets.businessinsider.com - May 23 at 1:18 PM
Surgalign to Participate at ISASS 2023 – 23rd Annual Conference Sponsored by the International Society for the Advancement of Spine Surgery and Medical Education ResourcesSurgalign to Participate at ISASS 2023 – 23rd Annual Conference Sponsored by the International Society for the Advancement of Spine Surgery and Medical Education Resources
finance.yahoo.com - May 23 at 1:18 PM
Surgalign Announces First Quarter 2023 Results and Provides Update on its Business Operations - Yahoo FinanceSurgalign Announces First Quarter 2023 Results and Provides Update on its Business Operations - Yahoo Finance
news.google.com - May 13 at 2:42 PM
Surgalign Holdings, Inc.: Surgalign Announces First Quarter 2023 Results and Provides Update on its Business OperationsSurgalign Holdings, Inc.: Surgalign Announces First Quarter 2023 Results and Provides Update on its Business Operations
finanznachrichten.de - May 12 at 10:12 AM
Surgalign: Q1 Earnings Snapshot - Seattle PISurgalign: Q1 Earnings Snapshot - Seattle PI
news.google.com - May 12 at 5:11 AM
Recap: Surgalign Holdings Q1 Earnings - Surgalign Holdings ... - BenzingaRecap: Surgalign Holdings Q1 Earnings - Surgalign Holdings ... - Benzinga
news.google.com - May 12 at 5:11 AM
Surgalign Announces First Quarter 2023 Results and Provides ... - GlobeNewswireSurgalign Announces First Quarter 2023 Results and Provides ... - GlobeNewswire
news.google.com - May 12 at 5:11 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

DocGo logo

DocGo

NASDAQ:DCGO
DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.
Evaxion Biotech A/S logo

Evaxion Biotech A/S

NASDAQ:EVAX
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.
FONAR logo

FONAR

NASDAQ:FONR
FONAR Corporation, together with its subsidiaries, engages in the research, development, production, and marketing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company operates in two segments, Medical Equipment, and Physician Management and Diagnostic Services. It provides Upright MRI scanner that allows patients to be scanned in weight-bearing conditions, such as standing, sitting, bending, or lying down. The company also offers non-medical management, including administrative services, billing and collection services, credentialing services, contract negotiations, compliance consulting, purchasing IT services, hiring, conducting interviews, training, supervision and management of non-medical personnel, storage of medical records, office space, equipment, repair maintenance services, accounting, assistance with compliance matters, and development and implementation of practice growth and marketing strategies. It owns and operates diagnostic imaging facilities in Florida; and manages MRI scanning facilities. The company markets its scanners to private diagnostic imaging centers and hospital outpatient imaging facilities. FONAR Corporation was founded in 1970 and is based in Melville, New York.
PhaseBio Pharmaceuticals logo

PhaseBio Pharmaceuticals

NASDAQ:PHAS
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.
Surgalign logo

Surgalign

NASDAQ:SRGA
Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spinal hardware implants and biomaterial products worldwide. It offers products for thoracolumbar procedures, including Streamline TL spinal fixation system, a system for degenerative and complex spine procedures; and Streamline MIS spinal fixation system, a range of implants and instruments used via a percutaneous or mini-open approach; and interbody fusion devices, as well as products for cervical procedures, such as CervAlign ACP system, a comprehensive anterior cervical plate system; Fortilink-C IBF system, a cervical interbody fusion device that utilizes TETRAfuse 3D technology; and Streamline OCT system, a range of implants used in the occipito-cervico-thoracic posterior spine. The company also provides motion preservation systems comprising Coflex Interlaminar Stabilization device for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression; HPS 2.0 Universal Fixation system, a pedicle screw system used for posterior stabilization of the thoracolumbar spine; and SImmetry SI Joint Fusion system, a minimally invasive surgical implant system to decrease opioid use, pain, and disability. In addition, it develops augmented reality and artificial intelligence digital surgery platform to enable digital spine surgery. The company markets its products through independent spine and biomaterial distributors to hospitals, ambulatory surgery centers, and healthcare providers, as well as through direct sales force. The company was incorporated in 1997 and is headquartered in Deerfield, Illinois. On June 19, 2023, Surgalign Holdings, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.